Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era

American Journal of Transplantation

Volumn 3, Issue 3, 2003, Pages 250-258

  Papatheodoridis, George V ^a   Sevastianos, Vasilios ^a   Burroughs, Andrew K ^b  

^a HIPPOKRATION HOSPITAL   (Greece)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Adefovir; Entecavir; Hepatitis B virus; Lamivudine; Liver transplantation; Nucleoside analogues

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ENTECAVIR; FAMCICLOVIR; GANCICLOVIR; HEPATITIS B ANTIBODY; LAMIVUDINE; NUCLEOSIDE ANALOG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; BIOAVAILABILITY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE LIVER FUNCTION RELATION; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; ERADICATION THERAPY; GRAFT REJECTION; HEPATITIS B VIRUS; HUMAN; INFECTION RISK; LIVER DISEASE; LIVER HISTOLOGY; LIVER PROTECTION; LIVER TRANSPLANTATION; NEPHROTOXICITY; PASSIVE IMMUNIZATION; PREOPERATIVE PERIOD; RECURRENCE RISK; REINFECTION; SHORT SURVEY; SIDE EFFECT; TREATMENT INDICATION; VIREMIA; VIRUS INFECTION; VIRUS MUTANT; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN;

ADENINE; ANTIVIRAL AGENTS; GUANINE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; LIVER TRANSPLANTATION; NUCLEOSIDES; PHOSPHONIC ACIDS; POSTOPERATIVE COMPLICATIONS; RECURRENCE; TIME FACTORS; TRANSPLANTATION IMMUNOLOGY;

EID: 0037355283     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-6143.2003.00063.x     Document Type: Short Survey

References (93)

1. Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991; 13: 619-626.
2. O'Grady JG, Smith HM, Davies SE et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992; 14: 104-111.
3. Davies SE, Portmann BC, O'Grady JG et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991; 13: 150-157.
4. Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology 2000; 32: 1189-1195.
5. Samuel D, Muller R, Alexander G et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842-1847.
6. Webster G, Barnes E, Burroughs A, Dusheiko G. Organ transplantation and discrimination. Patients with hepatitis B should not be given low priority. Br Med J 2000; 320: 1600-1601.
7. Feray C, Zignego AL, Samuel D et al. Persistent hepatitis B virus infection of mononuclear blood cells without concomitant liver infection. The liver transplantation model. Transplantation 1990; 49: 1155-1158.
8. , Terrault NA, Zhou S, Combs C et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996; 24: 1327-1333.
9. Gigou M, Feray C, Roche B et al. Residual HBV DNA at 10 years post-transplantation in patients receiving long-term anti-HBs immunoglobulins. Hepatology 2000; 32: 218A.
10. McGory RW, Ishitani MB, Oliveira WM et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996; 61: 1358-1364.
11. Yao FY, Osorio RW, Roberts JP et al. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg 1999; 5: 491-496.
12. Yoshida EM, Erb SR, Partovi N et al. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin, Liver Transpl Surg 1999; 5: 520-525.
13. van Hoek B, Kroes AC, Ringers J, Veenendaal RA, Terpstra OT, Lamers CB. Switching intravenous to out-of-hospital fixed-dose intramuscular hepatitis B immunoglobulin after liver transplantation for HBsAg-positive HBV-DNA negative cirrhosis is feasible and reduces cost. Hepatology 2000; 32: 242A.
14. Carman WF, Trautwein C, van Deursen FJ et al. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology 1996; 24: 489-493.
15. Ghany MG, Ayola B, Villamil FG et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis, Hepatology 1998; 27: 213-222.
16. Hunt CM, McGill JM, Allen ML, Condreay LD. Clinical relevance of hepatitis B virus mutations. Hepatology 2000; 31: 1037-1044.
17. Terrault NA, Zhou S, McCory RW et al. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology 1998; 28: 555-561.
18. Trautwein C, Schrem H, Tillmann HL et al. Hepatitis B virus mutations in the pre-S genome before and after liver transplantation. Hepatology 1996; 24: 482-488.
19. Terrault NA. Hepatitis B virus and liver transplantation. Clin Liver Dis 1999; 3: 389-415.
20. Hoofnagle JH, Di Bisceglie AM, Waggoner JG, Park Y. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 1993; 104: 1116-1121.
21. Villeneuve JP, Condreay LD, Willems B et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31: 207-210.
22. Kapoor D, Guptan RC, Wakil SM et al. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol 2000; 33: 308-312.
23. Kitay-Cohen Y, Ben-Ari Z, Tur-Kaspa R, Fainguelernt H, Lishner M. Extension of transplantation free time by lamivudine in patients with hepatitis B-induced decompensated cirrhosis. Transplantation 2000; 69: 2382-2383.
24. Liaw Y-F, Leung NWY, Chang T-T et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000; 119: 172-180.
25. Lau DTY, Khokhar MF, Doo E et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000; 32: 828-834.
26. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with HBeAg negative chronic hepatitis B. Hepatology 2000; 32: 847-851.
27. Merle P, Trepo C. Therapeutic management of hepatitis B-related cirrhosis. J Viral Hepat 2001; 8: 391-399.
28. Ling R, Mutimer D, Ahmed M et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplanted recipients with lamivudine. Hepatology 1996; 24: 711-713.
29. Fischer KP & Tyrrell DL, Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine (-) -beta-L-2′,3′-dideoxy-3′thiacytidine) in vitro. Antimicrobial Agents Chemother 1996; 40: 1957-1960.
30. Allen MI, Deslauriers M, Andrews CW et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998; 27: 1670-1677.
31. Zoulim F, Trepo C. Is lamivudine effective on Precore/Core promoter mutants of hepatitis B virus? Hepatology 2000; 32: 1172-1174.
32. Saab S, Kim M, Wright TL, Han SH, Martin P, Busuttil RW. Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus. Gastroenterology 2000; 119: 1382-1384.
33. Rosenau J, Bahr MJ, Tillmann HL et al. Lamivudine and lowdose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001; 34: 895-902.
34. Samuel D. Liver transplantation and hepatitis B virus infection: the situation seems to be under control, but the virus is still there, J Hepatol 2001; 34: 943-945.
35. Grellier L, Mutimer D, Ahmed M et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348: 1212-1215.
36. Mutimer D, Pillay D, Dragon E et al. High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatol 1999; 30: 715-721.
37. Mutimer D, Dusheiko G, Barrett C et al. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B, long-term follow-up. Transplantation 2000; 70: 809-815.
38. Malkan G, Cattral MS, Humar A et al. Lamivudine for hepatitis B in liver transplantation: a single-center experience. Transplantation 2000; 69: 1403-1407.
39. Wai CT, Lim SG, Tan KC. Outcome of lamivudine resistant hepatitis B virus infection in liver transplant recipients in Singapore. Gut 2001; 48: 581.
40. Fontana RJ, Keefe EB, Han S et al. Prevention of recurrent hepatitis B infection following liver transplantation: experience in 112 North American patients. Hepatology 1999; 30: 301A.
41. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998; 27: 628-633.
42. Mutimer D, Pillay D, Shields P et al. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut 2000; 46: 107-113.
43. Han SH, Ofman J, Holt C et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000; 6: 741-748.
44. Markowitz JS, Martin P, Conrad AJ et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28: 585-589.
45. McCaughan GW, Spencer J, Koorey D et al. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin. Liver Transpl Surg 1999; 5: 512-519.
46. Roche B, Samuel D, Roque AM et al. Intravenous anti HBs Ig combined with oral lamivudine for prophylaxis against HBV recurrence after liver transplantation. J Hepatol 1999; 30 (Suppl. 1): 80.
47. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000; 6: 429-433.
48. Lee PH, Hu RH, Tsai MK et al. Liver transplantation for patients with hepatitis B. prevention of hepatitis B recurrence by intravenous antihepatitis B immunoglobulin and lamivudine. Transplant Proc 2000; 32: 2245-2247.
49. Andreone P, Grazi GL, Gramenzi A et al. Lamivudine (LAM) plus HBIg combination therapy compared to HBIg or no therapy in preventing hepatitis B (HBV) recurrence after liver transplantation (LT). J Hepatol 2000; 32 (Suppl. 2): 51.
50. Buti M, Mass A, Prieto M et al. Randomized clinical trial of lamivudine vs lamivudine + hepatitis B gammaglobulin in the prevention of HBV recurrence after liver transplant - preliminary results. Hepatology 2000; 32: 217A.
51. Machicao VI, Soldevilla-Pico C, Devarbhavi HC, Lukens FJ, Ishitani MB, Dickson RC. Hepatitis B liver transplant patients on combination of lamivudine and high dose IV immune globulin have less significant histological progression than hepatitis C transplanted patients. Hepatology 2001; 34: 411A.
52. Marzano A, Salizzoni M, Debernardi-Venon W et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001; 34: 903-910.
53. Terrault NA, Wright TL. Combined short-term hepatitis B immunoglobulin (HBIG) and long-term lamivudine (LAM) versus HBIG monotherapy as hepatitis B virus (HBV) prophylaxis in liver transplant recipients, Hepatology 1998; 28: 389A.
54. Naoumov NV, Lopes AR, Burra P et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 2001; 34: 888-894.
55. Dodson SF, de Vera ME, Bonham CA, Geller DA, Rakela J, Fung JJ. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transpl 2000; 6: 434-439.
56. Sanchez-Fueyo A, Rimola A, Grande L et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: a new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 2000; 31: 496-501.
57. Angelico M, Di Paolo D, Trinito MO et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 2002; 35: 176-181.
58. Andreone P, Caraceni P, Grazi GL et al. Lamivudine treatment for acute hepatitis B after liver transplantation. J Hepatol 1998; 29: 985-989.
59. Nery JR, Weppler D, Rodriguez M, Ruiz P, Schiff ER, Tzakis AG. Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation. Transplantation 1998; 65: 1615-1621.
60. Perrillo R, Rakela J, Dienstag J et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group. Hepatology 1999; 29: 1581-1586.
61. Roche B, Samuel D, Roque AM et al. Lamivudine therapy for HBV infection after liver transplantation. J Hepatol 1999; 30 (Suppl. 1): 78.
62. Balan V, Dodson FS, Vargas HE et al. Long term follow up of lamivudine therapy for hepatitis B before and after liver transplantation; clinical implication of development of the YMDD mutant. Hepatology 1999; 30: 346A.
63. Seehofer D, Rayes N, Berg T et al. Lamivudine as first- and second-line treatment of hepatitis B infection after liver transplantation. Transpl Int 2000; 13: 290-296.
64. Fontana RJ, Hann HW, Wright T et al. A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation. Liver Transpl 2001; 7: 504-510.
65. Herrero JI, Quiroga J, Sangro B et al. Effectiveness of lamivudine in treatment of acute recurrent hepatitis B after liver transplantation. Dig Dis Sci 1998; 43: 1186-1189.
66. Brind AM, Bennett MK, Bassendine MF. Nucleoside analogue therapy in fibrosing cholestatic hepatitis - a case report in an HBsAg positive renal transplant recipient, Liver 1998; 18: 134-139.
67. Chan TM, Wu PC, Li FK, Lai CL, Cheng IK, Lai KN. Treatment of fibrosing cholestatic hepatitis with lamivudine. Gastroenterology 1998; 115: 177-181.
68. Seehofer D, Rayes N, Bechstein WO et al. Therapy of recurrent hepatitis B infection after liver transplantation. A retrospective analysis of 200 liver transplantations based on hepatitis B associated liver diseases. Z Gastroenterol 2000; 38: 773-783.
69. Ben-Ari Z, Mor E, Shapira Z, Tur-Kaspa R. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation. Liver Transpl 2001; 7: 113-117.
70. Rayes N, Seehofer D, Hopf U et al. Comparison of famciclovir and lamivudine in the long-term treatment of hepatitis B infection after liver transplantation. Transplantation 2001; 71: 96-101.
71. Seehofer D, Rayes N, Steinmuller T et al. Occurrence and clinical outcome of lamivudine-resistant hepatitis B infection after liver transplantation. Liver Transpl 2001; 7: 976-982.
72. Ben-Ari Z, Pappo O, Zemel R, Mor E, Tur-Kaspa R. Association of lamivudine resistance in recurrent hepatitis B after liver transplantation with advanced hepatic fibrosis. Transplantation 1999; 68: 232-236.
73. Peters MG, Singer G, Howard T et al. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin. Transplantation 1999; 68: 1912-1914.
74. Kruger M, Tillmann HL, Trautwein C et al. Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: a pilot study. Liver Transpl Surg 1996; 2: 253-262.
75. Singth N, Gayowski T, Wannstedt CF et al. Pretransplant famciclovir as prophylaxis for hepatitis B virus recurrence after liver transplantation. Transplantation 1997; 63: 1415-1419.
76. Gish RG, Lau JY, Brooks L et al. Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients. Hepatology 1996; 23: 1-7.
77. Roche B, Samuel D, Gigou M et al. Long-term ganciclovir therapy for hepatitis B virus infection after liver transplantation. J Hepatol 1999; 31: 584-592.
78. Deeks SG, Collier A, Larezra J et al. The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy in HIV-infected adults: a randomised, double-blind, placebo-controlled trial. J Infect Dis 1997; 176: 1517-1523.
79. Nevens F, de Man RA, Chua D et al. Effectiveness of a low dose of entecavir in treating recurrent viremia in chronic hepatitis B. Hepatology 2000; 32: 377A.
80. Wright H, Gavaler J, Van Thiel D. Preliminary experience with a-2b-interferon therapy in viral hepatitis in allograft recipients. Transplantation 1992; 53: 121-124.
81. Terrault NA, Holland CC, Ferrell L et al. Interferon alfa for recurrent hepatitis B infection after liver transplantation. Liver Transpl Surg 1996; 2: 132-138.
82. Ono-Nita SK, Kato N, Shiratori Y et al. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. J Clin Invest 1999; 103: 1635-1640.
83. Perrillo R, Schiff E, Yoshida E et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32: 129-134.
84. Ahmad J, Dodson SF, Balan V et al. Adefovir dipivoxil suppresses lamivudine resistant hepatitis B virus in liver transplant recipients. Hepatology 2000; 32: 292A.
85. Walsh KM, Woodall T, Lamy P, Wight DG, Bloor S, Alexander GJ. Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus. Gut 2001; 49: 436-440.
86. Mutimer D, Feraz-Neto BH, Harrison R et al. Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: rapid resolution during treatment with adefovir. Gut 2001; 49: 860-863.
87. Yang H, Westland CE, Delaney WE et al. Resistance monitoring in chronic hepatitis B patients exposed to adefovir dipivoxil for 72-136 weeks. The Hepatology Abstract 2001; 34: 316A.
88. de Man RA, Wolters L, Nevens F et al. A study of oral entecavir given for 28 days in both treatment-naïve and pre-treatment subjects with chronic hepatitis. Hepatology 2000; 32: 376A.
89. Tassopoulos N, Hadziyannis S, Cianciara J et al. Entecavir is effective in treating patients with chronic hepatitis B who have failed lamivudine therapy. Hepatology 2001; 34: 340A.
90. Mutimer D, Pillay D, Cook P et al. Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy. J Infect Dis 2000; 181: 713-716.
91. Tillmann HL, Trautwein C, Bock T et al. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation. Hepatology 1999; 30: 244-256.
92. Seehofer D, Rayes N, Berg T et al. Additional interferon alpha for lamivudine resistant hepatitis B infection after liver transplantation: a preliminary report. Transplantation 2000; 69: 1739-1742.
93. Honkoop P, de Man RA, Niesters HGM, Zondervan PE, Schalm SW. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000; 32: 635-639.